难治性特发性血小板减少性紫癜的治疗进展

特发性血小板减少性紫癜经脾切除和糖皮质激素治疗后仍需积极治疗定义为难治性特发性血小板减少性紫癜。目前糖皮质激素、免疫球蛋白、艾曲波帕 、罗米司亭、利妥昔单等已广泛应用于该病的治疗，但部分患者仍无疗效，进而有更多新型药物正在研发，如新型促血小板药物Avatrombopag（E5501）、抗CD20单克隆抗体（Veltuzumab）、Syk抑制剂（R788）、抗CD152抗体（Alemtuzumab）等，或者免疫抑制剂用于该病，如长春花碱、环孢素A、环磷酰胺等。也有针对于该病的新理论的提出需要临床验证。本文就围绕该病的治疗进展展开讨论。

Progress in Treatment of Refractory Idiopathic Thrombocytopenic Purpura

Abstract:Idiopathic thrombocytopenic purpura is still defined as refractory idiopathic thrombocytopenic purpura after splenectomy and glucocorticoid therapy.At present,glucocorticoids,immunoglobulin,atropa,romistin,rituximab and so on have been widely used in the treatment of the disease,but some patients still have no effect,and more new drugs are being developed.For example,a new platelet-stimulating drug named Avatrombopaga (E5501),a monoclonal antibody against CD20(Veltuzumab),Syk inhibitor(R788),anti CD152 antibody(Alemtuzumabis),or immunosuppressive agents for the disease,such as vinorelbine,cyclosporine A,cyclophosphamide, etc.There is also a need for clinical verification of new theories on the disease.This paper discusses the progress in the treatment of the disease.